LHFPL1 as A Potential Drug Target for Disruptions in Mitochondrial Function and Cellular Signaling Pathways

Target Name: LHFPL1

NCBI ID: G340596

LHFPL1

LHFPL1 as A Potential Drug Target for Disruptions in Mitochondrial Function and Cellular Signaling Pathways

The LHFPL1 (LHFPL tetraspan subfamily member 1) protein is a member of the LHFPL family, which is known for its role in the regulation of cell signaling pathways. LHFPL1 is expressed in various tissues and cells throughout the body, including the brain, heart, and gastrointestinal tract.

Recent studies have identified LHFPL1 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. This is due to LHFPL1's involvement in several cellular processes that are disrupted in these diseases, as well as its potential to modulate cellular signaling pathways.

One of the key functions of LHFPL1 is its role in the regulation of mitochondrial function. Mitochondria are organelles that are responsible for generating energy for the cell through a process called cellular respiration. LHFPL1 is known to interact with the protein complex known as the mitochondrial inner mitochondrial membrane protein (Mitofusin) complex, which is involved in regulating mitochondrial fusion and fusion-related processes.

Mitofusin is a protein that is composed of multiple subunits that are involved in regulating mitochondrial fusion and fusion-related processes. It is composed of the subunits MMP1, MMP2, MMP3, MMP4, and MMP5. MMP1 and MMP2 are the most well-studied subunits, and they are involved in the regulation of mitochondrial fusion and the formation of mitochondrial fission granules. MMP3 and MMP4 are also involved in the regulation of mitochondrial fusion, but their functions are not as well understood. MMP5 is a recently identified subunit that is involved in the regulation of mitochondrial fusion and has been shown to play a role in the development of certain neurodegenerative diseases.

LHFPL1 has been shown to interact with Mitofusin in various cellular processes, including the regulation of mitochondrial fusion and the formation of mitochondrial fission granules. This interaction between LHFPL1 and Mitofusin suggests that LHFPL1 may be a useful biomarker or drug target for diseases that are characterized by disruptions in mitochondrial function.

Another function of LHFPL1 is its role in the regulation of cellular signaling pathways. LHFPL1 is a member of the Tetraspan family, which is a group of proteins that are involved in the regulation of cell signaling pathways. Tetraspans are characterized by the presence of a unique nucleotide-binding oligomerization domain (NBO), which is responsible for the regulation of protein-protein interactions and the formation of tetraspan-protein interactions.

LHFPL1 is known to interact with several other proteins, including the protein kinase PDK4 (Pyk3), which is involved in the regulation of cellular signaling pathways. The interaction between LHFPL1 and PDK4 suggests that LHFPL1 may be a useful drug target or biomarker for diseases that are characterized by disruptions in cellular signaling pathways.

In addition to its role in the regulation of mitochondrial function and cellular signaling pathways, LHFPL1 is also involved in the regulation of cell adhesion. LHFPL1 is a member of the cadherin family, which is a group of transmembrane proteins that are involved in cell adhesion. LHFPL1 is known to interact with the protein E-cadherin, which is a key component of the cadherin complex. The interaction between LHFPL1 and E-cadherin suggests that LHFPL1 may be a useful drug target or biomarker for diseases that are characterized by disruptions in cell adhesion.

Given its involvement in

Protein Name: LHFPL Tetraspan Subfamily Member 1

The "LHFPL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LHFPL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets